Table 1.

Clinical characteristics of included SSc patients (n=42)

	Total N=42	ATA N=22	ACA N=20
Age, years, mean (SD)	57 (14)	52 (16)	62 (11)
Female, n (%)	30 (71%)	12 (55%)	18 (90%)
Duration since first non-Raynaud’s phenomenon symptom, months, median (IQR)	98 (50–160)	63 (39–102)	120 (95–221)
Diffuse cutaneous subset, n (%)	7 (17%)	7 (32%)	–
mRSS, median (IQR)	5 (2-7)	5 (2-7)	3 (0–8)
ILD on HRCT, n (%)	14 (33%)	14 (64%)	–
Renal crisis, n (%)	–	–	–
Pulmonary hypertension, n (%)	2 (5%)	–	2 (10%)
Current immunosuppressive use, n (%)	18 (43%)	12 (55%)	6 (30%)

Clinical characteristics were taken from the visit of the sample collection.

Immunosuppressive use included corticosteroids, azathioprine, methotrexate, mycophenolate mofetil, infliximab and hydroxychloroquine (see online supplemental table 1 for details).

ACA, anti-centromere antibodies; ATA, anti-topoisomerase antibodies; HRCT, high resolution CT; ILD, interstitial lung disease; mRSS, modified Rodnan Skin Score; SSc, systemic sclerosis.